摘要
目的探讨氯氮平联合氨磺必利治疗难治性精神分裂症的临床效果及安全性。方法选取我院2015年6月~2016年6月收治的80例精神分裂症患者,依照随机数字表法分为对照组和观察组,各40例。对照组给予氯氮平治疗,观察组给予氯氮平联合氨磺必利治疗。采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)在治疗12周后评定两组的临床疗效和药品不良反应。结果观察组治疗后的总有效率为80.0%,显著高于对照组的62.5%,差异有统计学意义(P<0.05)。观察组治疗后的PANSS总分、阴性及阳性症状评分显著低于对照组治疗后,差异有统计学意义(P<0.05)。两组治疗期间的不良反应比较,差异无统计学意义(P>0.05)。结论氯氮平联合氨磺必利治疗难治性精神分裂症的临床效果显著,不良反应较少,安全性高。
Objective To explore the efficacy and safety of Clozapine combined with Amisulpride in the treatment of refractory schizophrenia.Methods 80 patients with refractory schizophrenia admitted in our hospital from June 2015 to June 2016 were selected and divided into the control group and the observation group according to the random number table method,40 cases in each group.The control group was treated with Clozapine,the observation group was treated with Clozapine combined with Amisulpride.The PANSS and TESS were used to evaluate the clinical efficacy and ad- verse drug reactions of the two groups after 12 weeks of the treatment.Results The total effective rate after treatment of the observation group was 80.0%,which was significantly higher than that of the control group （62.5%）,with significant dift^rence （P〈0.05）.The total score of PANSS,the negative and positive symptom scores ＂after treatment in the observa- tion group was significantly lower than that in the control group,with significant difference （P〈0.05）.There was no significant difference in the incidence rate of adverse reactions between the two groups （P〉0.05）.Conclusion The curative effect of Clozapine combined with Amisulpride in the treatment of refractory schizophrenia is significant,it is safe with less adverse reaction.
出处
《中国当代医药》
2017年第14期112-114,共3页
China Modern Medicine
